CME credits: 0.25

Valid until: 31-03-2023

Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-new-data-for-namd-and-dme-in-vascular-integrity/13280/

Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.

=